Wells Fargo initiated coverage of Myriad Genetics with an Equal Weight rating and $20 price target. The firm sees long-term potential in Myriad’s expertise in genetic testing for oncology, women’s health, and mental health markets, but stays on the sidelines given both upside and downside near-term risks to core growth engine.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics initiated with bullish view at Guggenheim, here’s why
- Myriad Genetics initiated with bullish view at Wolfe Research, here’s why
- Myriad Genetics initiated with bullish view at Wolfe Research
- Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
- Myriad Genetics, Personalis enter pact for biomarker discovery platform